Abstract
Dimerized translationally controlled tumor protein (dTCTP) plays a role in allergic diseases. A 7-mer peptide, dimerized translationally binding protein 2 (dTBP2), binds to dTCTP and inhibits dTCTP, suggesting that the 7-mer peptide may have therapeutic potential. We assessed the safety of dTBP2 by examining its cytotoxicity to both human bronchial epithelial cells and mice. dTBP2 did not cause cytotoxicity to the epithelial cells in concentrations up to 100 μg/ml. Also, dTBP2 caused no adverse effects upon repeated administration of 50 mg/kg over 24 h to mice. Hence, we conclude that dTBP2 is a safe candidate drug for use in the therapy of allergic diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 1119-1125 |
| Number of pages | 7 |
| Journal | Human and Experimental Toxicology |
| Volume | 32 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2013 |
Bibliographical note
Funding Information:This study was supported by Ewha Global Top5 Grant 2011 of Ewha Womans University. Miyoung Kim was supported by RP-Grant 2011 of Ewha Womans University.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Dimerized TCTP
- allergy
- cytotoxicity
- dTBP2
- repeated-dose toxicity
- safety
Fingerprint
Dive into the research topics of 'A new antiallergic agent that binds to dimerized translationally controlled tumor protein and inhibits allergic symptoms is nontoxic'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver